about
Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitroHuman cytomegalovirus plasmid-based amplicon vector system for gene therapyFluorinated methylenecyclopropane analogues of nucleosides. Synthesis and antiviral activity of (Z)- and (E)-9-{[(2-fluoromethyl-2-hydroxymethyl)-cyclopropylidene]methyl}adenine and -guanineVirucidal activity of polysaccharide extracts from four algal species against herpes simplex virusNew small molecule entry inhibitors targeting hemagglutinin-mediated influenza a virus fusionHuman cytomegalovirus UL97 Kinase is required for the normal intranuclear distribution of pp65 and virion morphogenesisIn vitro activity and mechanism of action of methylenecyclopropane analogs of nucleosides against herpesvirus replicationL-valine ester of cyclopropavir: a new antiviral prodrug.Retinazone inhibits certain blood-borne human viruses including Ebola virus Zaire.Host immune system gene targeting by a viral miRNASynthesis and antiviral activity of 7-deazaneplanocin A against orthopoxviruses (vaccinia and cowpox virus).Synthesis and antiviral activities of new acyclic and "double-headed" nucleoside analoguesReassessing the organization of the UL42-UL43 region of the human cytomegalovirus strain AD169 genome.Synthesis and antiviral evaluation of 9-(S)-[3-alkoxy-2-(phosphonomethoxy)propyl]nucleoside alkoxyalkyl esters: inhibitors of hepatitis C virus and HIV-1 replicationCyclopropavir inhibits the normal function of the human cytomegalovirus UL97 kinase.Valganciclovir for symptomatic congenital cytomegalovirus diseaseHuman cytomegalovirus gene expression in long-term infected glioma stem cells.Antiviral activities of novel 5-phosphono-pent-2-en-1-yl nucleosides and their alkoxyalkyl phosphonoestersTAOK3 phosphorylates the methylenecyclopropane nucleoside MBX 2168 to its monophosphate.The natural antimicrobial peptide subtilosin acts synergistically with glycerol monolaurate, lauric arginate, and ε-poly-L-lysine against bacterial vaginosis-associated pathogens but not human lactobacilli.Orthopoxvirus targets for the development of antiviral therapies.Vaccinia virus lacking the deoxyuridine triphosphatase gene (F2L) replicates well in vitro and in vivo, but is hypersensitive to the antiviral drug (N)-methanocarbathymidineSynthesis and antiviral activity of 6-deoxycyclopropavir, a new prodrug of cyclopropavir.Synthesis and antiviral activities of methylenecyclopropane analogs with 6-alkoxy and 6-alkylthio substitutions that exhibit broad-spectrum antiviral activity against human herpesviruses.Conserved retinoblastoma protein-binding motif in human cytomegalovirus UL97 kinase minimally impacts viral replication but affects susceptibility to maribavirHuman cytomegalovirus UL97 kinase prevents the deposition of mutant protein aggregates in cellular models of Huntington's disease and ataxiaEffect of an immune enhancer, GPI-0100, on vaccination with live attenuated herpes simplex virus (HSV) type 2 or glycoprotein D on genital HSV-2 infections of guinea pigsOrthopoxvirus targets for the development of new antiviral agents.Human herpesvirus 6 U69 kinase phosphorylates the methylenecyclopropane nucleosides cyclopropavir, MBX 2168, and MBX 1616 to their monophosphates.Evaluation of AD472, a live attenuated recombinant herpes simplex virus type 2 vaccine in guinea pigs.(Z)- and (E)-2-(1,2-dihydroxyethyl)methylenecyclopropane analogues of 2'-deoxyadenosine and 2'-deoxyguanosine. Synthesis of all stereoisomers, absolute configuration, and antiviral activity.Phosphonate analogues of cyclopropavir phosphates and their E-isomers. Synthesis and antiviral activity.Antiviral evaluation of octadecyloxyethyl esters of (S)-3-hydroxy-2-(phosphonomethoxy)propyl nucleosides against herpesviruses and orthopoxviruses.Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir.Differential properties of cytomegalovirus pUL97 kinase isoforms affect viral replication and maribavir susceptibilityPre-clinical Assessment of C134, a Chimeric Oncolytic Herpes Simplex Virus, in Mice and Non-human Primates.The search for new therapies for human cytomegalovirus infections.Current and future therapies for herpes simplex virus infections: mechanism of action and drug resistance.The development of new therapies for human herpesvirus 6.Helicase-primase as a target of new therapies for herpes simplex virus infections.
P50
Q21142648-2EF0DE5A-1DFF-4581-BA1E-C597CDD18374Q24800764-A5C40187-2E9D-46B1-9D4F-FD7EE37B2CD0Q27485915-E60B8BAD-B8BE-4878-92DA-A725B68ED023Q27489390-8E7D21DE-C99D-4866-AF5D-372A8AED748CQ30355297-3879F2C1-C995-44C1-A64E-632122EA4E57Q33227757-D543F44A-EA07-44F7-9389-2D2CA78ED030Q33857275-65209013-758D-4159-8799-C5BF2D695E6FQ34096928-452ABA7C-22F1-4B8A-974C-B534138D6875Q34342378-6C432DC3-F02B-493F-8F02-4B5ABEF48E60Q34581221-357A6687-066D-467D-B0F9-F7F78D75DD08Q34684802-68C96145-249A-4A5F-AEB6-E22D7A668719Q34698954-8A9EFAF6-57AB-4380-9914-7F1A7889C864Q34813025-9C53C635-6A37-4B49-A987-A0FF2D9A2198Q35116027-3DF629C9-4D52-48F3-A16A-216AA8B65E63Q35270303-C0228698-6C0E-41BB-8365-E386DE7ABA3CQ35465712-EFB5A145-009D-4A10-A03F-92C3DCF3DBB5Q35535809-781F29F7-79DC-4B76-A404-53710295A9DAQ35636006-6885E41F-75C4-416D-8A42-C0F47AFC0EC5Q35638861-C77E685A-68DF-4C0C-840F-012A4BD3BE87Q35867431-1EA5C174-471B-48B9-85AE-2DA38FA69CBCQ36074391-F9B04FFE-ADC1-4D13-97FE-2BC41CF968D2Q36511768-2F48F9E0-2424-4C4F-BEC7-2AA4257110AAQ36950587-E6D9F03C-E9E1-4671-BF90-AF391565B4BFQ37036545-E6529BF4-AFC3-4CB8-8A49-2ADA81FCCE7EQ37085793-49D04CD6-3872-4EF2-A9CF-5E2C7ED91EE9Q37166304-E4BAB38B-6C3F-4DB7-9B02-A627D283313AQ37173293-80098C8A-2017-46A6-9D47-DBE63438E64AQ37173398-00622022-2C37-448C-ADA3-79B07F1BA146Q37263407-BAE8CAC5-D897-42E4-AD07-4F0415D981E1Q37283124-EDD7719C-7AEE-4835-B749-E56C07E68646Q37394720-53770A88-3478-470C-B053-5BB2D68DA953Q37394735-839436B3-FC0C-45E9-9470-58850FA1DF68Q37456244-E8D44C7C-9549-443E-9513-2AF51FD7A351Q37478310-B76EFF4F-1BE1-477D-BF4F-8DCD2AB56F21Q37713957-5448A3FB-FB46-47C3-A685-74E725843BC4Q37718569-77C30945-41CC-42CF-B0BA-D22B7E44C54BQ37811458-FF15AE04-5723-4CFC-AAFB-44A011A4AED7Q38230967-81F9700C-55D5-4A4B-A59C-82B93D9C1B8EQ38280949-3909F6DB-1661-4AD6-B9AD-3B4442F3D785Q38351481-8B5CCF22-6299-473A-BDB2-801FB7E3ECB7
P50
description
onderzoeker
@nl
researcher, ORCID id # 0000-0002-2720-6661
@en
name
Mark Prichard
@ast
Mark Prichard
@en
Mark Prichard
@es
Mark Prichard
@nl
type
label
Mark Prichard
@ast
Mark Prichard
@en
Mark Prichard
@es
Mark Prichard
@nl
prefLabel
Mark Prichard
@ast
Mark Prichard
@en
Mark Prichard
@es
Mark Prichard
@nl
P106
P1153
7003395831
P21
P31
P496
0000-0002-2720-6661